Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
36 results
D3.126 - Evaluation of Severe Pediatric Asthma Response to Biologics Using the Pediatric CONFiRM Score: A Real-Life Cohort Analysis
D3.127 - Evaluation of Serum Ezrin Levels and Spirometric and Plethysmographic Tests in Patients with Allergic and Non-Allergic Asthma
D3.128 - Management of Nasal Polyposis in Moderate-Severe Asthma Patients With Aspirin Desensitization And Biologic Agent Combination: Our Real-Life Experience With Seven Cases
D3.129 - Evaluation of Cardiovascular Disease Risk and Associated Factors in Childhood Asthma
D3.130 - PGI2 Signaling Attenuates the Proliferation and Type 2 Cytokine Production of Group 2 Innate Lymphoid Cells
D3.131 - Comparative Assessment of Exercise Provocation, and Impulse Oscillometry in Young Adults With Exercise-Induced Respiratory Symptoms
D3.132 - The impact of biological therapy on the quality of life of patients with severe asthma
D3.133 - Clinical Impact of Cumulative Oral Corticosteroid Exposure in Patients with Severe Asthma: Data from the Korean Severe Asthma Registry
D3.134 - Pulmonary rehabilitation at altitude: Is there an optimal season?
D3.135 - Real World Efficacy of Benralizumab Treatment in Severe Eosinophilic Asthma: A Single-Center Experience
D3.137 - The “Street Cat” Paradox: Low Prevalence but High Disease Burden of Mouse Sensitization in Pediatric Asthma
D3.138 - Can FeNO predict lung function decline in asthma? A 5-year multicenter cohort study
D3.139 - Asthma control and medication adherence in patients with asthma using preferred versus alternative GINA treatment tracks - a real-world observational study
D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study
D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study
D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study
D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial
D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial
D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial
D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download